An overnight incubation at 4 °C in a 1:1 DMSO/PBS solution under stirring prompted the loading of Gefitinib, an orally active, epidermal growth factor receptor (EGFR) tyrosine kinase (HR2) inhibitor that is part of breast cancer (SKBR3) therapy [57] within human H-chain ferritin [58]. The gene discussed is EGFR; the disease is breast cancer.